Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to examin the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 608 160 mg W0+80 mg Q2W | Experimental | Participants will receive starting dose of 160 milligrams (mg) 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection for 12 weeks. |
|
| 608 160 mg Q4W | Experimental | Participants will receive 160 milligrams 608 once every four weeks (Q4W) by subcutaneous injection for 12 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 608 Q2W | Drug | 608 160 mg at week 0 + 80 mg Q2W (5 cycles) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) | At Week 12 | |
| Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement | At Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) | At Week 12 | |
| Percentage of Participants Achieving a ≥100% Improvement in Psoriasis Area and Severity Index (PASI 100) | At Week 12 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Qinghong Zhou | Contact | +86 18911301578 | zhouqinghong@3sbio.com |
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42344898 | Derived | Cai L, Chen J, Wu L, Duan X, Zhang G, Li Y, Zhang L, Qin L, Zeng T, Wang X, Wang J, Huang K, Ren H, Liu L, Ding Y, Cui Y, Shan Y, Lu J, Tao X, Chen R, Tu Y, Yan M, Zhu X, Qiao N, Meng Z, Wang Y, Cheng F, Yuan Y, Zhu J, Hu X, Guo S, Xia X, Man X, Wu Z, Chen X, Chen G, He Y, Lv D, Feng Y, Deng D, Geng S, Guo Q, Feng W, Zhu X, Liu Y, Lin B, Xia R, Yu C, Fan J, Ji M, Lei T, Yang W, Yang M, Gao Y, Li W, Jiang M, Lou J, Liu Y, Zhou C, Zhang J. SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study. Front Immunol. 2026 Jun 9;17:1810418. doi: 10.3389/fimmu.2026.1810418. eCollection 2026. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 608 Q4W |
| Drug |
608 160 mg Q4W (3 cycles) |
|
| Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) | At Week 12 |
| Adverse events (AE) | 20 weeks |